Paclitaxel and its evolving role in the management of ovarian cancer

Nirmala Chandralega Kampan, Mutsa Tatenda Madondo, Orla M McNally, Michael Quinn, Magdalena Plebanski

Research output: Contribution to journalReview ArticleResearchpeer-review

225 Citations (Scopus)


Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

Original languageEnglish
Article number413076
Number of pages22
JournalBioMed Research International
Publication statusPublished - 2015

Cite this